These outcomes suggest that DBP potentially promotes lipid accumulation and disrupts the metabolic equilibrium of NAFLD by activating the SREBP1-c/FAS signaling pathways. Here, FAS is linked to metabolic dysfunction-associated steatotic liver disease.